Media
Media
Our latest announcements
Hansa Biopharma publishes disclosure document for admission to trading of shares on Nasdaq Stockholm
Regulatory press release
02/10/2025
Hansa Biopharma has carried out a directed share issue of 17 million shares, raising proceeds of approximately USD 71 million
Regulatory press release
02/10/2025
Hansa Biopharma intends to carry out a directed share issue of approximately USD 60 million
Regulatory press release
01/10/2025
Genethon to present preliminary efficacy and safety data from Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 at ESGCT congress 2025
26/09/2025
Media articles
Insights
The Power of Hope: Redefining Treatment Decisions for Highly Sensitized Kidney Patients
07/08/2025
Collaboration across the continuum of care to improve equity for highly sensitized people in kidney transplantation
17/07/2024
A concerted collaboration to advance treatment options for people living with rare diseases
26/06/2024
Fueling the future: the role of biotech in advancing innovative science and delivering new medicines
02/05/2024
Patients' perspective
Life on tour with chronic kidney disease
“I had always played the guitar and wrote songs but never really did anything with it. Nothing was going to hold me back now! No more excuses… there wasn’t time!”
Patients' perspective
Suspended time: a journey from diagnosis to transplant
"Dialysis may sound simple, but it isn’t, and over the course of his treatment Ron underwent several different kinds, all of which made him feel awful."
